What is the current share price of Novartis India Limited (NOVARTIND)?

As of the latest market update, Novartis India Limited (NOVARTIND) is trading at ₹1,494.6. The stock has moved 1.93% up in the recent session.

What is the technical sentiment for NOVARTIND stock?

Based on our proprietary technical analysis, the current signal for NOVARTIND is "NEUTRAL". This analysis considers over 20+ indicators including RSI, MACD, and moving average crossovers to gauge market momentum.

What is the 52-week high and low for Novartis India Limited?

Novartis India Limited has seen a 52-week high of ₹1,589.2 and a 52-week low of ₹950. Comparing the current price to these levels helps investors understand the stock's relative valuation and volatility over the past year.

Which sector does Novartis India Limited belong to?

Novartis India Limited operates in the Healthcare sector, specifically within the Pharmaceuticals & Biotechnology industry. Its performance is often influenced by broader trends in the Healthcare segment.

What is the market capitalization of NOVARTIND?

Novartis India Limited (NOVARTIND) has a market capitalization of approximately ₹3.69K Cr. This classifies it as a small cap stock in the Indian market.

NOVARTIND

NSE

Novartis India Limited (SMALL CAP)

Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals

₹1,494.60

28.30 (1.93%)

High VOLATILITY

As on 10 Jul 2026

Advanced Chart

Price History

Market Cap

The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.

₹3.69K Cr

SMALL CAP

P/E Ratio

Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.

N/A

Industry

The specific business sector the company operates in. Useful for comparing with similar companies.

Pharmaceuticals

52-Week Range

The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.

52W Low₹950+57.3%

52W High₹1,589.2-6.0%

Current Price

₹1,494.60

Circuit Limits (20%)

The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.

Lower Circuit₹1,195.68

Upper Circuit₹1,793.52

Reference Price

₹1,494.60

Investment Checklist

Ascending Channel on 1D — target ₹1539.44

Cup and Handle on 1D — target ₹1696.7

Trend: Price above all key MAs — strong uptrend

Volume divergence: Bearish (price up, volume down)

SuperTrend(10,3): Price below SuperTrend (Industry Standard (Swing/Medium-Term))

Technical Analysis

Analysis from 2026-07-10

Confidence

77%

Trend

BULLISH

Price above all key MAs — strong uptrend

EMA20

1429.72

EMA50

1312.19

Price Action

MIXED

NEUTRAL

Higher Highs3

Higher Lows6

Lower Highs6

Lower Lows3

Support & Resistance Levels

Resistance (Above)

₹1554.00

₹1589.20

Support (Below)

₹1276.03

₹1059.90

₹950.00

Volume Analysis

TrendDECREASING

Change-44.60%

Unusual VolumeNo

Divergence Detected

Bearish (price up, volume down)

Stop Loss Levels

Fixed Risk

1% Risk₹1479.65

3% Risk₹1449.76

5% Risk₹1419.87

7% Risk (Custom)

₹1389.98

Technical Levels

1x ATR (Volatility)₹1433.06

2x ATR (Swing)₹1371.52

3x ATR (Trend)₹1309.98

Immediate Support₹1276.03

Moving Averages

EMA 9 (Short-term)₹1460.29

EMA 20 (Medium-term)₹1429.72

EMA 50 (Trend)₹1312.19

Financials

Financial data not available

Peer Comparison

Pharmaceuticals

Peer Comparison

Symbol	Name	Price	Change	P/E Ratio	Market Cap
SUNPHARMA	Sun Pharmaceutical Industries Limited	₹1,935.50	-0.17%	40.2	₹4.64L Cr large Cap
DIVISLAB	Divi's Laboratories Limited	₹6,836.00	+0.34%	70.4	₹1.81L Cr large Cap
TORNTPHARM	Torrent Pharmaceuticals Limited	₹4,901.50	+0.07%	77.5	₹1.66L Cr large Cap
CIPLA	Cipla Limited	₹1,439.40	-0.13%	30.1	₹1.16L Cr large Cap
ZYDUSLIFE	Zydus Lifesciences Limited	₹1,150.80	-0.71%	23.0	₹1.16L Cr large Cap
LUPIN	Lupin Limited	₹2,496.30	-0.28%	21.4	₹1.14L Cr mid Cap
MANKIND	Mankind Pharma Limited	₹2,525.10	-0.27%	54.3	₹1.04L Cr mid Cap
DRREDDY	Dr. Reddy's Laboratories Limited	₹1,244.30	-1.99%	25.6	₹1.04L Cr large Cap
AUROPHARMA	Aurobindo Pharma Limited	₹1,564.70	-1.43%	26.1	₹90.88K Cr mid Cap
LAURUSLABS	Laurus Labs Limited	₹1,537.80	+2.02%	91.5	₹83.02K Cr mid Cap
NOVARTIND	Novartis India Limited	₹1,494.60	+1.93%	—	₹3.69K Cr small Cap

Corporate Information

Large Deals

View All

Bulk, Block and Short deals reported for this stock.

Loading Deals...

Corporate Events

Upcoming results & meetings

View All

No upcoming events found

We couldn't find any scheduled corporate actions for this symbol at the moment.

Latest News

News for NOVARTIND

View All

Novartis India launches Pluvicto for prostate cancer treatment

negative

ET Markets - Industry 25d ago

Novartis India launches Pluvicto for prostate cancer treatment

Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer cells, offering a new treatment approach for metastatic prostate cancer. The therapy will be available through select hospitals and nuclear medicine centers across India.

NOVARTINDPRECISIONAutomobile and Auto ComponentsHealthcare

Read full story

India needs to remain attractive for innovation-led investment: Judith Love, Novartis

positive

ET Markets - Industry 29d ago

India needs to remain attractive for innovation-led investment: Judith Love, Novartis

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The company underscores the importance of collaboration to tackle obstacles like high costs and inadequate infrastructure.

BFINVESTNOVARTINDFinancial ServicesHealthcare

Read full story

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

negative

ET Markets - Industry 40d ago

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.

FOCUSNOVARTINDConsumer DurablesHealthcare

Read full story

NOVARTIND

Price History

Investment Checklist

Technical Analysis

Technical Analysis

Trend

Price Action

Support & Resistance Levels

Volume Analysis

Stop Loss Levels

Fixed Risk

Technical Levels

Moving Averages

Financials

Peer Comparison

Peer Comparison

Corporate Information

Large Deals

Corporate Events

Latest News

News for NOVARTIND

Novartis India launches Pluvicto for prostate cancer treatment

India needs to remain attractive for innovation-led investment: Judith Love, Novartis

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Frequently Asked Questions

What is the current share price of Novartis India Limited (NOVARTIND)?

What is the technical sentiment for NOVARTIND stock?

What is the 52-week high and low for Novartis India Limited?

Which sector does Novartis India Limited belong to?

What is the market capitalization of NOVARTIND?